Article

M&S Technologies, Holladay introduce latest in contrast sensitivity systems

Washington, DC &#8212 Three years in development, the Holladay Automated Contrast Sensitivity System (HACSS) is expected to offer many features that are lacking or problematic with many of the current CFS systems on the market today.

April 18 - Washington, DC - Three years in development, the Holladay Automated Contrast Sensitivity System (HACSS) is expected to offer many features that are lacking or problematic with many of the current CFS systems on the market today.

Jack Holladay, MD, of Baylor College, Houston, and M&S Technologies (Booth #1226) introduced the HACSS, a CFS system, during a Sunday breakfast briefing.

In introducing the HACSS, Dr. Holladay discussed the principles of contrast sensitivity, which measures the limit of person's ability to see. Dr. Holladay also outlined what he believes are the problems with current CFS systems, including brightness, vertical linear gratings, the blanking period, response time, and false positives.

Dr. Holladay discussed some of the features of the HACSS that address these problems. The system has rotationally symmetric targets and randomly presents optotypes. It provides a technician-free, computer-driven platform that significantly reduces testing time to 10 minutes per eye with tight standard deviation due to the design and presentation of the optotypes.

Other features include:

• Standardized illumination with certification on brightness and color temperature.

• An automated user-interactive testing mechanism that eliminates technician bias.

• Testing protocol that allows screen blanking for a pre-determined period of time to allow the retina to completely refresh between displays.

• System allows for maximum response time for all patient inputs, eliminating focus.

• Automatic report printing, graphing, and output to any media for data collection.

• Conforms to ANSI guidelines for CFS testing.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.